SourceBio International PLC (AIM:SBI)’s latest update showed results materially ahead of expectations, said Liberum.
Topline and EBITDA upgrades of 7% and 15%, drop through to a meaningful 16.5% upgrade in adjusted EPS added the broker.
Strong cash conversion meanwhile leaves SourceBio with a cash pile of £33.3m (debt-free) leaving capital earmarked for future M&A.
"The outlook in the non-COVID core business is improving with trading at pre-pandemic levels and we anticipate growth to accelerate through 2022, although forecasting visibility of COVID PCR testing volumes remains low.
“Reflecting the greater cash balance into our valuation, we increase our TP from 190p to 205p offering 30% upside.”
Buy is the recommendation from Liberum.